• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Breaking News: Toms Shoes Founder Pledges $100 million for Psychedelic Research

Microdose NewsDesk by Microdose NewsDesk
June 21, 2023
in Breaking News
Reading Time: 1 min read
A A
donation to psychedelics

Donation is believed to be the largest ever in the psychedelics space

 

Blake Mycoskie, founder of Toms Shoes, has pledged to give $100 million to support psychedelic research and access.

In an interview with MarketWatch, Mycoskie said the money will help fund research, support academic institutions studying psychedelic medicine, and nonprofits working to increase access for patients in need of psychedelic treatments.

In the interview, Mycoskie said his personal experience with psychedelic therapy in 2017 (ayahuasca) led to see the potential for healing, saying that psychedelics “cracked me open, and it connected me more to my faith in God, made me feel that we were all connected and everything was fine and perfect…I came back just feeling like, wow, that was more powerful than any therapy I’d ever done.”

[bsa_pro_ad_space id=2]
ADVERTISEMENT

And as for the donation, $100 million works out to approx a quarter of Mycoskie’s net worth — what many are calling the most generous donation

Continue on your trip...

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Buy Prescription Lasix

to psychedelics ever. Blake Mycoskie told MarketWatch: ”We really need to get this right, and we really need to have these foundations and nonprofits funded properly … I felt a real sense of urgency.”

Read the full interview here.

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
A Deeper Look at the Clinical Trial Process and FDA Approval of Psychedelics

MDMA Legalization: The Road to Legal MDMA and FDA Approval of Psychedelics

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.